Author(s): Beeching NJ, Clarke PD, Kitchin NR, Pirmohamed J, Veitch K,
Abstract Share this page
Abstract A prospective, randomised, observer-blind, comparative study was performed in healthy adults with a new hepatitis A/typhoid combined vaccine, Viatim, and the marketed Hepatyrix vaccine. Both vaccines induced high levels of protective antibodies, but typhoid responses were higher and hepatitis A responses more rapid with Viatim compared with Hepatyrix. Both vaccines were well tolerated, no serious adverse events (SAEs) occurred, but more Viatim vaccinees had more mild or moderate local reactions (82.7\%) than Hepatyrix (53.1\%, p < 0.001). In this direct comparison Viatim induced more local reactions, but elicited a more rapid and higher immune response to both antigens than Hepatyrix.
This article was published in Vaccine
and referenced in Journal of Vaccines & Vaccination